Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BAX crawled time : 12:20 save search
Baxter Reports First-Quarter 2023 Results
Published: 2023-04-27 (Crawled : 12:20) - biospace.com/
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: 2.0%
H: 2.05%
C: -0.43%
results
Insights on the Local Anesthesia Drugs Global Market to 2027 - by Drug Type, Mode of Administration, Distribution Channel and Region
Published: 2023-01-28 (Crawled : 12:20) - prnewswire.com
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
| Email alert
Add to watchlist
ENDP | $0.2926 -9.6%
|
Health Technology
| Email alert
Add to watchlist
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
drug global distribution market
Baxter Reports Second-Quarter 2022 Results
Published: 2022-07-28 (Crawled : 12:20) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.12%
H: 2.36%
C: 2.36%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.02%
H: 0.99%
C: 0.56%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: -7.56%
H: 1.47%
C: -3.64%
results
Valued to be $3.4 Billion by 2026, Critical Care Therapeutics Slated for Robust Growth Worldwide
Published: 2022-06-27 (Crawled : 12:20) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.34%
H: 1.72%
C: 0.95%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: -0.01%
H: 0.97%
C: -0.09%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -1.52%
H: 0.67%
C: -0.88%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 1.23%
H: 0.57%
C: -1.48%
ABEO | $7.6 0.93% 0.92% 390K
|
Health Technology
|
| O: 2.35%
H: 9.2%
C: 5.23%
care therapeutics growth
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
Published: 2014-11-06 (Crawled : 12:20) - globenewswire.com
MACK 4 | $14.72 0.27% 0.27% 76K
|
Health Technology
| Email alert
Add to watchlist
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
phase 1 cancer brain cancer phase 3 phase 2 train
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
Published: 2014-11-19 (Crawled : 12:20) - globenewswire.com
MACK 4 | $14.72 0.27% 0.27% 76K
|
Health Technology
| Email alert
Add to watchlist
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
fda fda fast track fast track cancer pancreatic fast track designation gemcitabine pancreas designation
Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research
Published: 2014-12-04 (Crawled : 12:20) - globenewswire.com
MACK 4 | $14.72 0.27% 0.27% 76K
|
Health Technology
| Email alert
Add to watchlist
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
cancer research preclinical pre-clinical
Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
Published: 2015-01-20 (Crawled : 12:20) - globenewswire.com
MACK 4 | $14.72 0.27% 0.27% 76K
|
Health Technology
| Email alert
Add to watchlist
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
test cancer gastrointestinal phase 3 symposium
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.